IP Library › Granted Patent US 8,202,978
Granted Patent B2
US 8,202,978 · App. 12/253,090 · Granted Jun 19, 2012

Compositions for detecting group A streptococci

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,978
App. No.
12/253,090
Granted
Jun 19, 2012
Kind
B2
Abstract

Compositions, methods and kits for detecting Group A streptococci. Particularly described are oligonucleotides that are useful as amplification primers and hybridization probes for detecting very low levels of Group A streptococci nucleic acids.

Claims (21)

1. A composition for amplifying in a transcription associated amplification reaction and detecting in real time a Streptococcus pyogenes target nucleic acid sequence, said composition comprising:

a first primer, the base sequence of which consists of a 3′ terminal target-complementary sequence and, optionally, a first primer upstream promoter sequence that is non-complementary to a nucleic acid containing said target nucleic acid sequence or its complement, said 3′ terminal target-complementary sequence of said first primer being selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, allowing for the presence of RNA equivalents and nucleotide analogs;

a second primer, the base sequence of which consists of a 3′ terminal target-complementary sequence and, optionally, a second primer upstream promoter sequence that is non-complementary to a nucleic acid containing said target nucleic acid sequence or its complement, said 3′ terminal target-complementary sequence of said second primer being selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, allowing for the presence of RNA equivalents and nucleotide analogs; and

a molecular beacon probe, the base sequence of which consists of a target-complementary sequence and a pair of mutually complementary base sequences that are non-complementary to a nucleic acid containing said target nucleic acid sequence or its complement, said target-complementary sequence of said probe being selected from the group consisting of SEQ ID NO:23, SEQ ID NO:24 and SEQ ID NO:25, allowing for the presence of DNA equivalents and nucleotide analogs.

2. The composition of claim 1 , wherein said first primer comprises said first primer upstream promoter sequence.

3. The composition of claim 2 , wherein said first primer upstream promoter sequence comprises a promoter sequence for T7 RNA polymerase.

4. The composition of claim 1 , wherein said probe is up to 30 bases in length.

5. The composition of claim 1 , wherein said probe further comprises a fluorophore moiety and a quencher moiety.

6. The composition claim 1 , wherein said probe further comprises a detectable label.

7. The composition of claim 6 , wherein said detectable label of said probe is selected from the group consisting of a chemiluminescent label and a fluorescent label.

8. The composition of claim 1 , wherein the base sequence of said first primer is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18, allowing for the presence of RNA equivalents and nucleotide analogs.

9. The composition of claim 1 , wherein the base sequence of said second primer is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, allowing for the presence of RNA equivalents and nucleotide analogs.

10. The composition of claim 1 , wherein the base sequence of said probe is selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, allowing for the presence of DNA equivalents and nucleotide analogs.

11. The composition of claim 1 , wherein:

the base sequence of said first primer is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18, allowing for the presence of RNA equivalents and nucleotide analogs;

the base sequence of said second primer is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, allowing for the presence of RNA equivalents and nucleotide analogs; and

the base sequence of said probe is selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, allowing for the presence of DNA equivalents and nucleotide analogs.

12. The composition of claim 1 , wherein:

the base sequence of said first primer is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18;

the base sequence of said second primer is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7; and

the base sequence of said probe is selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2012
From: POLLNER, REINHOLD B.; DARBY, PAUL M.
To: GEN-PROBE INCORPORATED
Reel/Frame 027652/0367 →